fc188 casino login ph
Victor Wembanyama and Anthony Edwards will play Christmas Day games for the first time on Wednesday as the NBA delivers its 77th year of contests on the holiday. French centre Wembanyama, last season's NBA Rookie of the Year, will lead the San Antonio Spurs into New York to face the Knicks, who have the league's longest holiday history. The Knicks have played the most Christmas games of any NBA club at 56 entering this year, the first coming in 1947, the year the first NBA Christmas game was played. Wembanyama, a 20-year-old who stands 7-foot-3 (2.21m), averages 24.8 points, 9.9 rebounds, 3.9 assists and 4.0 blocked shots a game for the Spurs, who return to the Christmas lineup for the first time in eight years. "Very excited just about spending Christmas in New York," Wembanyama said. "Going to be like the movies I hope, maybe get a little snow. "I'll approach it just like any other game. We've got to learn about their team, scout them and apply it for sure. I'm sure it's going to be special. I'm sure the league is going to make it something special that we're going to be able to feel." Edwards, a two-time NBA All-Star guard who helped the United States capture gold at the Paris Olympics, will try to spark the Minnesota Timberwolves on a holiday road trip to Dallas in a rematch of last season's Western Conference finals. "Ant-Man" leads the T-Wolves with 25.3 points a game and also has 5.5 rebounds, 4.0 assists and 1.4 steals a contest this season. The league's past three champions will also take the court on Wednesday with the defending champion Boston Celtics playing host to Philadelphia, the 2022 trophy-lifting Golden State Warriors playing host to the Los Angeles Lakers and the 2023 winner Denver Nuggets on the road at Phoenix. Lakers star LeBron James, who turns 40 next Monday, is the NBA career leader in points on Christmas with 476 in a record 18 games on December 25. He and former Miami teammate Dwyane Wade share the lead in wins by a player on Christmas with 10. The Lakers and Knicks share the NBA record for Christmas wins by a team with 24 for each. This year marks the 40th anniversary of Bernard King scoring 60 points, the highest NBA total on Christmas Day. Three other players -- Rick Barry, Wilt Chamberlain and Slovenian Luka Doncic -- have scored 50 or more in a game on the holiday. Dallas guard Doncic joined the club with a 50-point effort last year. The Lakers (16-13) and Golden State (15-13) are fighting for seventh in the Western Conference just ahead of San Antonio (15-14) and Minnesota and Phoenix, both 14-14. Dallas is fourth in the West at 19-10, just ahead of Denver 16-11. The Celtics are second in the Eastern Conference at 22-7, ahead of New York (19-10) while Philadelphia has struggled to a 10-17 start, 12th in the East. js/pbScottie Scheffler goes on birdie run, takes two-shot lead at Hero World Challenge
Ifedi starts at left tackle for Browns in prime-time matchup against AFC North-leading SteelersCRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") CTOR , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $ - Capital Contribution of due to related party by parent $ 33,180,961 $ - Prepaid Manufacturing transferred to Inventory $ 6,134,895 $ - View original content to download multimedia: https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339671.html SOURCE Citius Oncology, Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Scheffler goes on a run of birdies in the Bahamas and leads by 2
Beyond evangelicals, Trump and his allies courted smaller faith groups, from the Amish to Chabad
487 Tons of NOx Emissions Reduced, 93% to Benefit Environmental Justice Areas DIAMOND BAR, Calif. , Dec. 6, 2024 /PRNewswire/ -- Today, the South Coast Air Quality Management District (South Coast AQMD) Governing Board approved more than $109 million to accelerate the development of zero-emission charging and hydrogen infrastructure. This funding will deliver heavy-duty electric chargers and hydrogen refueling stations along critical trade corridors, including the San Pedro Bay Ports and major freeways, with a strong focus on environmental justice communities. Once completed, the projects will reduce approximately 487 tons of smog-forming nitrogen oxides (NOx) and seven tons of particulate matter annually, improving air quality for the region's most impacted areas. Of the 30 projects, 12 are located within Assembly Bill (AB) 617 communities, with 93% of the emissions reductions directly benefiting underserved areas. Key infrastructure developments include 21 electric charging stations equipped with more than 800 connectors and fast chargers for heavy-duty trucks and seven hydrogen refueling stations, including a flagship location at California State University, Los Angeles , dedicated to workforce training and community education. "These investments provide critical support needed for heavy-duty vehicle fleet owners to embrace cleaner technologies," said Vanessa Delgado , South Coast AQMD's Governing Board Chair. "By prioritizing projects like these, we're not just addressing pollution, but also ensuring equitable access to the benefits of a zero-emission future." In December 2023 , South Coast AQMD launched a solicitation for zero-emission infrastructure proposals under its Carl Moyer Program and received nearly $400 million in applications, demonstrating the demand for zero emission heavy duty trucks and other equipment. Projects, in part, were selected based on their ability to deliver public access, cost-effectiveness and maximum impact on the South Coast Air Basin's air quality. Additionally, the initiative is fostering collaborations with school districts like Los Angeles Unified and Moreno Valley Unified to advance the adoption of zero-emission school buses. The California State University of Los Angeles hydrogen station will not only serve fuel cell vehicles but also educate and train the next generation on hydrogen technology. For more information on the awarded projects, please visit https://www.aqmd.gov/docs/default-source/Agendas/Governing-Board/2024/2024-dec6-004.pdf?sfvrsn=2 South Coast AQMD is the regulatory agency responsible for improving air quality for large areas of Los Angeles , Orange , Riverside and San Bernardino counties, including the Coachella Valley. For news, air quality alerts, event updates and more, please visit us at www.aqmd.gov , download our award-winning app, or follow us on Facebook , X (formerly known as Twitter) and Instagram . MEDIA CONTACT: Nahal Mogharabi , (909) 396-3773, Cell: (909) 837-2431 Connie Villanueva (909) 396-2409, Cell: (909) 215-5601 [email protected] SOURCE SOUTH COAST AQMDUS President-elect Donald Trump filed a brief Friday urging the Supreme Court to pause a law that would ban TikTok the day before his January 20 inauguration if it is not sold by its Chinese owner ByteDance. "In light of the novelty and difficulty of this case, the court should consider staying the statutory deadline to grant more breathing space to address these issues," Trump's legal team wrote, to give him "the opportunity to pursue a political resolution." Trump was fiercely opposed to TikTok during his 2017-21 first term, and tried in vain to ban the video app on national security grounds. The Republican voiced concerns -- echoed by political rivals -- that the Chinese government might tap into US TikTok users' data or manipulate what they see on the platform. US officials had also voiced alarm over the popularity of the video-sharing app with young people, alleging that its parent company is subservient to Beijing and that the app is used to spread propaganda, claims denied by the company and the Chinese government. Trump called for a US company to buy TikTok, with the government sharing in the sale price, and his successor Joe Biden went one stage further -- signing a law to ban the app for the same reasons. Trump has now, however, reversed course. "Now (that) I'm thinking about it, I'm for TikTok, because you need competition," he recently told Bloomberg. "If you don't have TikTok, you have Facebook and Instagram -- and that's, you know, that's Zuckerberg." Facebook, founded by Mark Zuckerberg and part of his Meta tech empire, was among the social media networks that banned Trump after attacks by his supporters on the US Capitol on January 6, 2021. The ban was driven by concerns that he would use the platform to promote more violence. Those bans on major social media platforms were later lifted. In the brief filed on Friday, Trump's lawyer made it clear the president-elect did not take a position on the legal merits of the current case. "President Trump takes no position on the underlying merits of this dispute," John Sauer wrote in the amicus curiae -- or "friend of the court" -- brief. "Instead, he respectfully requests that the court consider staying the act's deadline for divestment of January 19, 2025, while it considers the merits of this case, thus permitting President Trump's incoming Administration the opportunity to pursue a political resolution of the questions at issue in the case." ft/aha